PATENT CLAIM ANALYSIS

Application Number: 16097506
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "338000"]

Abstract:
The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.

Claim (Index 15):
A method for treatment or prophylaxis of lymphoma, macular degeneration, psoriasis, lupus erythematosus, multiple sclerosis, COPD, gout, NASH, hepatic fibrosis, insulin resistance, metabolic syndrome, spondyloarthritis, rheumatoid arthritis, endometriosis, endometriosis-related pain, or other endometriosis-associated symptoms, comprising administering to a patient in need thereof comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to  claim 7 .

Metadata:
- Claim Count in Document: 42.0
- Percentile: 97.0
- Lexical Diversity: 1.30556
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16097463', '16097065', '15529996', '15106073', '13856666']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.727290697015536
- 35 USC 102 Novelty (BERT): 0.5095466279548888
- Combined Prediction Score: 0.7055162901094713
- Mean Citation Score: 266.679436
- Max Citation Score: 294.3370700000001
- Similarity Product: 230.5976779267133

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test